JP2020519659A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519659A5
JP2020519659A5 JP2019563101A JP2019563101A JP2020519659A5 JP 2020519659 A5 JP2020519659 A5 JP 2020519659A5 JP 2019563101 A JP2019563101 A JP 2019563101A JP 2019563101 A JP2019563101 A JP 2019563101A JP 2020519659 A5 JP2020519659 A5 JP 2020519659A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519659A (ja
JP7218306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032726 external-priority patent/WO2018213281A1/en
Publication of JP2020519659A publication Critical patent/JP2020519659A/ja
Publication of JP2020519659A5 publication Critical patent/JP2020519659A5/ja
Application granted granted Critical
Publication of JP7218306B2 publication Critical patent/JP7218306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563101A 2017-05-15 2018-05-15 神経変性疾患を治療するための組成物 Active JP7218306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506226P 2017-05-15 2017-05-15
US62/506,226 2017-05-15
PCT/US2018/032726 WO2018213281A1 (en) 2017-05-15 2018-05-15 Compositions for treating neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2020519659A JP2020519659A (ja) 2020-07-02
JP2020519659A5 true JP2020519659A5 (https=) 2021-07-26
JP7218306B2 JP7218306B2 (ja) 2023-02-06

Family

ID=64274594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563101A Active JP7218306B2 (ja) 2017-05-15 2018-05-15 神経変性疾患を治療するための組成物

Country Status (14)

Country Link
US (3) US11214540B2 (https=)
EP (1) EP3634394B1 (https=)
JP (1) JP7218306B2 (https=)
KR (1) KR102614814B1 (https=)
CN (1) CN110869011B (https=)
AU (1) AU2018269964B2 (https=)
BR (1) BR112019023851A2 (https=)
DK (1) DK3634394T3 (https=)
ES (1) ES3063712T3 (https=)
IL (1) IL270251B2 (https=)
MX (1) MX388366B (https=)
NZ (2) NZ799802A (https=)
WO (1) WO2018213281A1 (https=)
ZA (1) ZA201907238B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) * 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
IL303592A (en) * 2020-12-11 2023-08-01 Cognition Therapeutics Inc Compositions for treating dry age-related macular degeneration (amd)
EP4308565A4 (en) 2021-03-19 2025-01-01 Cognition Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
DE2753278A1 (de) 1977-11-30 1979-05-31 Basf Ag Aralkylpiperidinone
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
DE3222152A1 (de) * 1982-06-12 1983-12-15 Bayer Ag, 5090 Leverkusen Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
IL70813A (en) 1983-01-31 1987-10-30 Lilly Co Eli Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH01305085A (ja) * 1988-05-31 1989-12-08 Yamanouchi Pharmaceut Co Ltd ピリジルチアゾリジンカルボン酸アミド誘導体
JPH02215789A (ja) * 1989-02-15 1990-08-28 Yamanouchi Pharmaceut Co Ltd チアゾロ[3,4―a]ピラジン誘導体
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
JPH06321781A (ja) 1993-05-13 1994-11-22 Yamanouchi Pharmaceut Co Ltd 血小板活性化因子拮抗剤
JPH0714147A (ja) 1993-06-25 1995-01-17 Dainippon Printing Co Ltd 磁気記録媒体および磁気記録媒体の記録方法
JPH07145147A (ja) * 1993-11-26 1995-06-06 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
DE19529411A1 (de) * 1995-08-10 1997-02-13 Bayer Ag Substituierte Tetrahydro-5-nitro-pyrimidine
JP3522930B2 (ja) 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
WO1997040051A1 (en) 1996-04-24 1997-10-30 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
JP4329290B2 (ja) * 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
ES2365602T3 (es) 2001-03-05 2011-10-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Proteínas oligoméricas tipo chaperona, estables a desnaturalizantes y/o resistentes a proteasa, polinucleótidos que codifican las mismas y sus usos.
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
EP1453528B1 (en) 2001-12-14 2009-07-22 Council of Scientific and Industrial Research Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders
JP4329381B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US7829562B2 (en) 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
EP1644026A4 (en) 2003-06-12 2007-10-24 Ms Science Corp SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
CZ2006628A3 (cs) 2004-03-12 2007-01-24 Egis Gyogyszergyár Nyrt. Kombinovaná farmaceutická kompozice pro inhibici poklesu kognitivních funkcí
TW200538052A (en) 2004-05-31 2005-12-01 Kaneka Corp Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006027252A1 (en) 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
WO2006094724A2 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
KR20080041624A (ko) 2005-06-15 2008-05-13 대릭 에스. 에치. 엘. 김 베타-아밀로이드 단백질-유발 안질환의 치료 방법
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
KR20090007564A (ko) 2006-03-17 2009-01-19 허발사이언스 싱가포르 피티이 리미티드 쿠르쿠마 종을 포함한 추출물 및 이를 수득하는 방법
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2007126473A2 (en) 2006-04-10 2007-11-08 Oligomerix, Inc. Oligomerization of amyloid proteins
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
CA2662723A1 (en) 2006-09-08 2008-03-13 Vib Vzw Means and methods for the production of amyloid oligomers
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20080131233A1 (en) 2006-10-17 2008-06-05 Yao Chun I Plate-shaped fastener device
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
CA2684920A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of treating cognitive disorders by inhibition of gpr12
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
US20090246191A1 (en) 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009059214A1 (en) 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
US20110092554A1 (en) 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
CN102203124A (zh) 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物,其寡聚物,用于制备的方法以及包括所述类似物或寡聚物的组合物,及其用途
WO2010062260A1 (en) 2008-11-29 2010-06-03 The Thailand Research Fund Virus and target cell interaction inhibition
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
PE20120578A1 (es) 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
ES2581178T3 (es) 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
CN102595884B (zh) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
US20150160228A1 (en) 2010-02-05 2015-06-11 Susan Catalano Compositions and method for determining the efficacy of amyloidosis treatments
WO2011106785A2 (en) 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
BR112013019775A2 (pt) 2011-02-02 2017-04-18 Cognition Therapeutics Inc composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
EP2747759A4 (en) 2011-08-25 2015-05-13 Cognition Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP2747768A4 (en) 2011-08-25 2015-10-21 Cognition Therapeutics Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) * 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
WO2019089988A1 (en) 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN110283082A (zh) 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法
IL303592A (en) 2020-12-11 2023-08-01 Cognition Therapeutics Inc Compositions for treating dry age-related macular degeneration (amd)

Similar Documents

Publication Publication Date Title
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
JP2020519659A5 (https=)
JP2020023528A5 (https=)
JP2019521988A5 (https=)
JP2016040288A5 (https=)
RU2004131641A (ru) Новые соединения
JP2018070614A5 (https=)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2023524821A5 (https=)
RU2006101452A (ru) Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора
JP2015532295A5 (https=)
JP2020529994A5 (https=)
JP2017524733A5 (https=)
RU2015143610A (ru) Лечение катаплексии
JP2003535843A5 (https=)
JP2016516074A5 (https=)
RU2016134751A (ru) Соединения
JP2015531764A5 (https=)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JP2017531619A5 (https=)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2018522861A5 (https=)
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
JP2019535723A5 (https=)